CTRI/2015/09/006211已完成2 期
An open label, single arm, multi-centered study to evaluate the efficacy, safety and tolerability of lipid based tacrolimus ointment 0.1% in patients of oral lichen planus - NA
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female participants between 18 and 65 years of age
- •2.Confirmed diagnosis of symptomatic oral lichen planus
- •3.Symptomatic OLP (Spontaneous or meal related oral pain).
排除标准
- •1.Asymptomatic lichen planus with no ulcerated or erythematous oral lesions.
- •2.Who have received systemic immunosuppressants, oral retinoids or any other systemic therapies known or suspected to have an effect on lichen planus within 4 weeks prior to participation in the study.
- •3.Who have been treated with topical therapy
- •4.Severe or recurrent systemic or generalized infections (bacterial, viral or fungal).
- •5.Who have unstable or uncontrolled diabetes or hypertension.
- •6.Hypersensitivity to tacrolimus or any of the ointment excipients, pimecrolimus, any macrolides such as clindamycin, erythromycin, azithromycin, clarithyromycin, etc.
研究者
相似试验
已完成
3 期
A Study of Tacrolimus Ointment of Intas Pharmaceuticals Limited, India in Patients having Inflammatory Condition with ulcer affecting mucous membranes inside the mouthCTRI/2018/05/013796Intas Pharmaceuticals Ltd154
进行中（未招募）
不适用
An open-label, single arm, multicenter study to assess the safety and efficacy of once-weekly administration of NeoRecormon using the 30.000 IU prefilled syringe in anaemic adult patients with solid tumors treated with non-platinum containing chemotherapy - PANTHERAnaemia in adult patients with solid tumors treated with non-platinum containing chemotherapyMedDRA version: 8.1Level: PTClassification code 10049105EUCTR2005-004189-17-BE.V. Roche S.A.
进行中（未招募）
1 期
An Open Label, Single Arm, Multicentre Study of Lynparza (Olaparib) Capsules in Relapsed BRCA Mutated Ovarian Cancer Patients (ORZORA)EUCTR2015-000734-30-PLAstraZeneca AB275
进行中（未招募）
1 期
An Open Label, Single Arm, Multicentre Study of Lynparza (Olaparib) Capsules in Relapsed somatic or germline BRCA Mutated Ovarian Cancer Patients (ORZORA)BRCA Mutated Ovarian Cancer PatientsMedDRA version: 19.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000734-30-HUAstraZeneca AB250
进行中（未招募）
1 期
An Open Label, Single Arm, Multicentre Study of Lynparza (Olaparib) Capsules in Relapsed BRCA Mutated Ovarian Cancer Patients (ORZORA)EUCTR2015-000734-30-GBAstraZeneca AB275